CARDIOVASCULAR

CARDIOVASCULAR

Starting with the development of a unique cell-based system for the identification of compounds modulating cardiac rhythm, Fluofarma developed key capacities to support drug discovery in the field of cardiovascular diseases.

Hypertension in vitro model

NEW !   Endothelial cell activation HUVECs PF 1.6

Cardiac activity recording

NEW! Calcium assay iPSC-derived cardiomyocytes:
iCell2®		 PF 1.7 ⤵ TEST SHEET
NEW ! MEA assay iPSC-derived cardiomyocytes:
Cor 4U® – iCell2®		 CV 5.14
hERG channel HEK 293 CV 5.6
hERG trafficking HEK 293 CV 5.10
hNav1.5 channel HEK 293 CV 5.7
hKir2.1 channel HEK 293 CV 5.8
hKir2.1 trafficking HEK 293 CV 5.13
hCav1.2 channel HEK 293 CV 5.9
Inositol triphosphate receptor
channel function		 H9C2 Cells PF 3.21
EX VIVO
Spontaneously beating right atrium Guinea-pig – Rabbit CV 5.1
Stimulated left atrium Guinea-pig – Rabbit CV 5.11
Purkinje fiber Rabbit – Dog CV 5.5
Papillary muscle Guinea-pig CV 5.12

A UNIQUE CARDIAC ARRHYTHMIA CELL-BASED ASSAY

> human induced Pluripotent Stem Cell derived Cardiomyocytes (iPSC-CMs) are functionally synced, spontaneously generating heart-beating cycles

> High-throughput monitoring of calcium bursts by FLIPR® Tetra, to identify compounds modulating cardiac rhythm

> A cell-based system suited for screening, drug profiling and cardiotoxicity studies

ADDITIONAL CAPABILITIES